Prevalence of skeletal-related events in hormone-naive prostate cancer in a low resource setting

• Published in: The Nigerian postgraduate medical journal 2022-07, Vol.29 (3), p.268-271
• Main Authors: Ugwumba, Fredrick, Nnabugwu, Ikenna, Okoh, Agharighom, Echetabu, Kevin, Onwuasoigwe, Okechukwu, Nwosu, Ekeoma
• Format: Article
• Language: English
• Subjects: Biopsy; Bone diseases; Complications and side effects; gleason score; Health aspects; initial presentation; Prostate cancer; Risk factors; skeletal-related events; Socially handicapped; Statistics; symptom duration
• ISSN: 1117-1936; 2468-6875
• DOI: 10.4103/npmj.npmj_70_22

Background: Presentation with symptoms of advanced prostate cancer is prevalent in developing societies. The objective of this study was to determine the rate of and factors associated with skeletal-related events (SREs) at presentation with hormone-naïve prostate cancer. Methods: Records of 331 consecutive prostate cancer patients from January 2009 to April 2018 were reviewed. The prevalence of SRE at the presentation was determined. In addition, the relationships between SRE and age of patient, duration of clinical features, serum total prostate-specific antigen (tPSA) and biopsy Gleason score (GS) at presentation were evaluated. Analyses were done with IBM SPSS® version 25. Results: Mean age was 69.8 ± 8.0 years. While 43.8% of patients had lower urinary tract symptoms (LUTS) only, 51.4% had LUTS and other features of disease progression. Only 2.1% of the cases were confirmed from screen detection of elevated serum tPSA. SREs were observed in 11.8% at first presentations with hormone-naïve prostate cancer. Symptom duration (odds ratio [OR] 0.94; 95% confidence interval [CI] 0.90-0.99; P = 0.02), anaemia that could not be attributed to gross haematuria or external blood loss (OR 9.6; 95% CI 3.12-29.52; P < 0.001) and transrectal biopsy GS (OR 1.61; 95% CI 1.17-2.22; P = 0.003 ) were significantly associated with SREs at presentation with hormone-naïve prostate cancer. Conclusions: Evidence exists that patients who present with SREs from more aggressive prostate cancers may have had more rapid symptom progression, but not a longer delay before presentation.